Literature DB >> 11331365

Ezrin-dependent promotion of glioma cell clonogenicity, motility, and invasion mediated by BCL-2 and transforming growth factor-beta2.

W Wick1, C Grimmel, C Wild-Bode, M Platten, M Arpin, M Weller.   

Abstract

Ezrin belongs to the ezrin-radixin-moesin family proteins, which cross-link actin cytoskeleton and plasma membrane. Malignant glioma cells are paradigmatic for their strong migratory and invasive properties. Here, we report that the expression of dominant-negative ezrins inhibits clonogenicity, migration, and invasiveness of human malignant glioma cells. Furthermore, dominant-negative ezrins block hepatocyte growth factor (HGF)-mediated stimulation of clonogenicity and migration, without altering HGF-induced protein kinase B/Akt and focal adhesion kinase phosphorylation. Glioma cells expressing dominant-negative ezrins exhibit a shift of the BCL-2/BAX rheostat toward apoptosis, reduced alpha(V)beta(3) integrin expression and reduced matrix metalloproteinase (MMP) expression and activity. These changes are associated with a dramatic loss of transforming growth factor beta(2) (TGF-beta(2)) release. Exogenous supplementation of TGF-beta(2) overcomes the inhibitory effects of dominant-negative ezrins on migration and clonogenicity. A neutralizing TGF-beta(2) antibody mimics the effects of dominant-negative ezrins on clonogenicity and migration. Exogenous HGF markedly induces TGF-beta(2) protein levels, and a neutralizing TGF-beta(2) antibody abolishes the HGF-mediated increase in glioma cell motility. Finally, TGF-beta(2) does not modulate BCL-2 or BAX expression, but BCL-2 gene transfer increases the levels of latent and active TGF-beta(2). Intracranial xenografts of U87MG glioma cells transfected with the dominant-negative ezrins in athymic mice grow to significantly smaller volumes, and the median survival of these mice is 50 d compared with 28 d in the control group. These data define a novel pathway for HGF-induced glioma cell migration and invasion, which requires ezrin, changes in the BCL-2/BAX rheostat, and the induction of TGF-beta(2) expression in vitro, and underscore the important role of HGF signaling in vivo.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331365      PMCID: PMC6762489     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  36 in total

1.  Apoptosis is accompanied by changes in Bcl-2 and Bax expression, induced by loss of attachment, and inhibited by specific extracellular matrix proteins in mammary epithelial cells.

Authors:  G R Merto; N Cella; N E Hynes
Journal:  Cell Growth Differ       Date:  1997-02

2.  Regulation of endothelial CD44 expression and endothelium-tumour cell interactions by hepatocyte growth factor/scatter factor.

Authors:  S Hiscox; W G Jiang
Journal:  Biochem Biophys Res Commun       Date:  1997-04-07       Impact factor: 3.575

3.  Ezrin immunoreactivity is associated with increasing malignancy of astrocytic tumors but is absent in oligodendrogliomas.

Authors:  K D Geiger; P Stoldt; W Schlote; A Derouiche
Journal:  Am J Pathol       Date:  2000-12       Impact factor: 4.307

4.  Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression.

Authors:  M Platten; W Wick; C Wild-Bode; S Aulwurm; J Dichgans; M Weller
Journal:  Biochem Biophys Res Commun       Date:  2000-02-16       Impact factor: 3.575

5.  Adenovirus-mediated delivery of antisense gene to urokinase-type plasminogen activator receptor suppresses glioma invasion and tumor growth.

Authors:  P M Mohan; S K Chintala; S Mohanam; C L Gladson; E S Kim; Z L Gokaslan; S S Lakka; J A Roth; B Fang; R Sawaya; A P Kyritsis; J S Rao
Journal:  Cancer Res       Date:  1999-07-15       Impact factor: 12.701

6.  CD44 interaction with c-Src kinase promotes cortactin-mediated cytoskeleton function and hyaluronic acid-dependent ovarian tumor cell migration.

Authors:  L Y Bourguignon; H Zhu; L Shao; Y W Chen
Journal:  J Biol Chem       Date:  2000-11-17       Impact factor: 5.157

Review 7.  ECM-mediated glioma cell invasion.

Authors:  R H Goldbrunner; J J Bernstein; J C Tonn
Journal:  Microsc Res Tech       Date:  1998-11-01       Impact factor: 2.769

8.  BCL-2 promotes migration and invasiveness of human glioma cells.

Authors:  W Wick; S Wagner; S Kerkau; J Dichgans; J C Tonn; M Weller
Journal:  FEBS Lett       Date:  1998-12-04       Impact factor: 4.124

9.  Integrin binding specificity of laminin-10/11: laminin-10/11 are recognized by alpha 3 beta 1, alpha 6 beta 1 and alpha 6 beta 4 integrins.

Authors:  Y Kikkawa; N Sanzen; H Fujiwara; A Sonnenberg; K Sekiguchi
Journal:  J Cell Sci       Date:  2000-03       Impact factor: 5.285

10.  Ezrin contains cytoskeleton and membrane binding domains accounting for its proposed role as a membrane-cytoskeletal linker.

Authors:  M Algrain; O Turunen; A Vaheri; D Louvard; M Arpin
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

View more
  33 in total

1.  Trabedersen to target transforming growth factor-beta: when the journey is not the reward, in reference to Bogdahn et al. (Neuro-Oncology 2011;13:132-142).

Authors:  Wolfgang Wick; Michael Weller
Journal:  Neuro Oncol       Date:  2011-05       Impact factor: 12.300

2.  Trimodal glioblastoma treatment consisting of concurrent radiotherapy, temozolomide, and the novel TGF-β receptor I kinase inhibitor LY2109761.

Authors:  Mengxian Zhang; Tobias W Herion; Carmen Timke; Na Han; Kai Hauser; Klaus J Weber; Peter Peschke; Ute Wirkner; Michael Lahn; Peter E Huber
Journal:  Neoplasia       Date:  2011-06       Impact factor: 5.715

Review 3.  Glioma cell invasion: regulation of metalloproteinase activity by TGF-beta.

Authors:  W Wick; M Platten; M Weller
Journal:  J Neurooncol       Date:  2001-06       Impact factor: 4.130

4.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets.

Authors:  Dominique B Hoelzinger; Luigi Mariani; Joachim Weis; Tanja Woyke; Theresa J Berens; Wendy S McDonough; Andrew Sloan; Stephen W Coons; Michael E Berens
Journal:  Neoplasia       Date:  2005-01       Impact factor: 5.715

5.  Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway.

Authors:  Kartik Krishnan; Ben Bruce; Stephen Hewitt; Dafydd Thomas; Chand Khanna; Lee J Helman
Journal:  Clin Exp Metastasis       Date:  2006-09-22       Impact factor: 5.150

6.  Rosiglitazone suppresses glioma cell growth and cell cycle by blocking the transforming growth factor-beta mediated pathway.

Authors:  Peng Wang; Jinpu Yu; Qiang Yin; Wenliang Li; Xiubao Ren; Xishan Hao
Journal:  Neurochem Res       Date:  2012-06-16       Impact factor: 3.996

7.  Inhibitors of Glioma Growth that Reveal the Tumour to the Immune System.

Authors:  Manuel Nieto-Sampedro; Beatriz Valle-Argos; Diego Gómez-Nicola; Alfonso Fernández-Mayoralas; Manuel Nieto-Díaz
Journal:  Clin Med Insights Oncol       Date:  2011-09-21

8.  HOXA10 promotes cell invasion and MMP-3 expression via TGFβ2-mediated activation of the p38 MAPK pathway in pancreatic cancer cells.

Authors:  Xian-Ping Cui; Cheng-Kun Qin; Zhen-Hai Zhang; Zhong-Xue Su; Xin Liu; Shi-Kang Wang; Xing-Song Tian
Journal:  Dig Dis Sci       Date:  2014-01-25       Impact factor: 3.199

9.  Reciprocal regulation by estradiol 17-beta of ezrin and cadherin-catenin complexes in pituitary GH3 cells.

Authors:  Perry M Smith; C Amanda Heinrich; Stacey Pappas; John J Peluso; Ann Cowan; Bruce A White
Journal:  Endocrine       Date:  2002-04       Impact factor: 3.633

10.  The role of the membrane cytoskeleton cross-linker ezrin in medulloblastoma cells.

Authors:  Hirokatsu Osawa; Christian A Smith; Young Shin Ra; Paul Kongkham; James T Rutka
Journal:  Neuro Oncol       Date:  2008-12-16       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.